Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 73

Showing 26-50 of 73 citing articles:

Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma
Ruilan Ma, Dian Yang, Peng Wang, et al.
Biology Direct (2025) Vol. 20, Iss. 1
Open Access
A prognostic signature of Glutathione metabolism-associated long non-coding RNAs for lung adenocarcinoma with immune microenvironment insights
Junxi Hu, Shuyu Tian, Qingwen Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Drugging Challenging Cancer Targets Using Fragment-Based Methods
Stephen W. Fesik
Chemical Reviews (2025)
Open Access
Spatial distribution and activation changes of T cells in pancreatic tumors according to KRAS mutation subtype
Ji Hye Jeong, Dakyum Shin, Sang‐Yeob Kim, et al.
Cancer Letters (2025), pp. 217641-217641
Open Access
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Joyeeta Roy, Rima Mouawad, Armita Kyani, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Advocating for change—Integration of efforts across the drug discovery and development continuum
Timothy P. Heffernan, Giulio Draetta
Cancer Cell (2025)
Closed Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Carolin Schneider, Valentina Spielmann, Christian Braun, et al.
Translational Oncology (2025) Vol. 55, pp. 102366-102366
Closed Access
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Khvaramze Shaverdashvili, Timothy F. Burns
Cancer (2025) Vol. 131, Iss. S1
Open Access
Covalent inhibitors possessing autophagy-modulating capabilities: charting novel avenues in drug design and discovery
Yutong Wang, Shiyu Luo, Hongbao Sun, et al.
Drug Discovery Today (2025), pp. 104347-104347
Closed Access
Road Map to Defeat Pancreatic Cancer
L. Paige Ferguson, David A. Tuveson
Annual Review of Cancer Biology (2025) Vol. 9, Iss. 1, pp. 1-20
Closed Access
Precision Oncology in Pancreatic Cancer and Future Treatment Directions
Layal Al Mahmasani, Eileen M. O’Reilly
Surgical Oncology Clinics of North America (2025)
Closed Access
Synthetic Approaches and Clinical Application of KRAS Inhibitors for Cancer Therapy
M. Jiang, Shaowei Ma, Ying Xuan, et al.
European Journal of Medicinal Chemistry (2025) Vol. 291, pp. 117626-117626
Closed Access
Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
İsa Taş, Reinhilde Jacobs, Juliane Albrecht, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy
Jingjing Shi, Xiaoyan Cui, Junlin Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Mapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics
Jiangwei Song, Busong Wang, Mingjie Zou, et al.
Biology (2025) Vol. 14, Iss. 5, pp. 477-477
Open Access
Vaccines as Prophylactics and Therapeutics
Priyal Bagwe, Sharon Vijayanand, Amitabh Gaur
(2025), pp. 35-91
Closed Access
Penetrative Biomimetic Nanovehicle Boosts Immunotherapy in Triple-Negative Breast Cancer via SOS1 Blockade
Jiaxin Zhang, Xian Peng, Chao Wang, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101064-101064
Open Access
Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer
Hongyu Liu, Chao Zhou, Jun Lü, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays
Thomas Gerstberger, Helmut Berger, Frank Büttner, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 3
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study
Shiro Takamatsu, R. Tyler Hillman, Kosuke Yoshihara, et al.
British Journal of Cancer (2024)
Closed Access | Times Cited: 3

Scroll to top